Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
about
The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokineticsSafety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adultsPhase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weighDevelopment of a humanized monoclonal antibody with therapeutic potential against West Nile virusThe pharmacological basis of anti-IgE therapyA recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments.Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen.Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety.Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting.Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2Mouse-human immunoglobulin G1 chimeric antibodies with activities against Cryptococcus neoformans.Prolonged urticaria with 17-1A antibody.Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain.The emerging role of radioimmunotherapy in haematological malignancies.A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma.Advances in interleukin 2 receptor targeted treatmentNew approaches to antibody therapy.Development of a humanized antibody with high therapeutic potential against dengue virus type 2Inhibition of metastatic tumor formation in vivo by a bacteriophage display-derived galectin-3 targeting peptide.IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.Human leukocyte differentiation antigens as therapeutic targets: the CD molecules and CD antibodies.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseasesRituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.The ICAM-1 antisense oligonucleotide ISIS-3082 prevents the development of postoperative ileus in mice.Etanercept ameliorates inflammation and pain in a novel mono-arthritic multi-flare model of streptococcal cell wall induced arthritis.Primary lack of efficacy of infliximab therapy for rheumatoid arthritis: pharmacokinetic characterization and assessment of switching to tocilizumab.Predictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.Building better monoclonal antibody-based therapeutics.Controlled-release and local delivery of therapeutic antibodies.The birth pangs of monoclonal antibody therapeutics: the failure and legacy of CentoxinAdjuvant therapy of ovarian cancer with radioactive monoclonal antibodym17-1A-, c17-1A- and cSF25-mediated antibody-dependent cell-mediated cytotoxicity in patients with advanced cancerDrug targeting with monoclonal antibodies. A review.Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic miceThe role of basiliximab induction therapy in organ transplantation.Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.Implications of EGFR PharmDx kit for cetuximab eligibility.A simple methodology for conversion of mouse monoclonal antibody to human-mouse chimeric form.Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.Humanization of murine monoclonal antibodies through variable domain resurfacing.
P2860
Q24561800-8936047F-951E-4CF6-AFBE-C6CD07EE3FA4Q24645675-1352DF89-A27F-4387-9994-949D8D8A9CDCQ24654724-92119102-3F96-4E71-8B48-3D73CB0B7203Q27473186-7F58DC1B-157E-48C0-81A5-A11B582764C1Q28143946-251537B9-39FC-4223-BC52-88F978BE5795Q30657795-DF34F787-075B-4744-98B1-38BB278726D6Q31076446-F4C117B5-DEA4-4532-92BB-1EDA0FC84005Q33641577-2DB83913-C418-4326-9D39-AD53BDAC9CADQ33685694-4F32311B-A348-45EC-971D-9616D6D01028Q33712484-CB5A41CC-22AA-437E-8D1C-6548B2AA34ABQ33754371-A6E02BC5-D9F6-429F-8C1B-7231FEB4775EQ33867577-1309C1DD-E2B3-4BD1-8BCF-4EDE228CFC2BQ33880904-6E0129E2-95EE-46E6-8D6C-098330A78648Q33904384-CCB8B7E3-171A-4EA6-A80A-D61A9B23040AQ33907508-B0CEE53D-D39A-40C9-994D-1BE71A8D04C2Q34071328-27F23BDC-F403-43D0-B19D-7CF897601D72Q34130569-7F16BF5D-FC2C-425B-86D3-A53513B6FE06Q34260219-CB374760-4C41-4C25-A26E-202D687EB42BQ34360666-BA91D4CE-4343-4208-8C41-9D310315F73EQ34451934-6FC0C104-6BB4-4D60-85FD-FFA9D052E6A1Q34451956-6126AE28-6728-42E1-A3F4-A084F0D2151FQ34536782-A388C07F-013E-4B3B-8FBD-B0A03FE01A8FQ34733916-0B7F4C8E-A48E-4793-9D2F-7C806FC1CD96Q35049145-1DC5553C-C525-432C-89F8-710596416BB2Q35060214-39AB2829-080A-448B-8B3D-959E5B25D1CFQ35610243-80B59E49-4334-4FD3-A699-BD52CCD1C380Q35752167-9078309F-7E34-44B6-9883-12C5B90F4149Q35817552-FA05EA92-D741-4BEE-8BE7-C5BB53E725F0Q35842644-D583F2B9-326C-4909-96F6-2E882D45D355Q35969881-6305F033-C43D-4204-BC1B-18F8D9B1AEACQ35977304-6BC83514-E08E-4FCA-90C0-18F241E04448Q36079704-86099CF6-4407-466C-B12D-AE6A5F73723AQ36351254-85F04A64-C50A-4641-8095-B826C0CCA047Q36476514-59EE5306-8F35-45A8-9676-FECD3C8E47F5Q36675465-50223F3B-6FCC-4FC3-AF0B-798657433190Q36752014-189D9FCD-5780-4C26-BF31-34219166D68BQ37118974-09034115-9720-4682-89B5-D602ECFE02B0Q37178059-9B391E66-50AB-4608-98BC-2B7102DBAA07Q37457154-8223C558-A7E8-49C8-856D-B3868CE0BF4BQ37558400-56D18E0F-D9EE-4207-88F1-63C272E058B0
P2860
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
description
1989 nî lūn-bûn
@nan
1989 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
name
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@ast
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@en
type
label
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@ast
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@en
prefLabel
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@ast
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@en
P2093
P2860
P356
P1476
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
@en
P2093
A F LoBuglio
E B Harvey
M B Khazaeli
R H Wheeler
P2860
P304
P356
10.1073/PNAS.86.11.4220
P407
P577
1989-06-01T00:00:00Z